<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897698</url>
  </required_header>
  <id_info>
    <org_study_id>4-1326/2021</org_study_id>
    <nct_id>NCT04897698</nct_id>
  </id_info>
  <brief_title>Probiotics for Weight Loss</brief_title>
  <official_title>LB001 Study: Probiotics for Weight Loss: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>deFair Medical AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate a compound of probiotics and prebiotics in females and males with&#xD;
      overweight with the aim to evaluate the effect on weight and metabolic markers.&#xD;
&#xD;
      The design is a three month randomized doubled-blinded, three-armed placebo-controlled trial&#xD;
      of probiotics for weight loss. Normal dose (2 capsules รก 0.4g per day) doubled dose (4&#xD;
      capsules รก 0.4g per day), or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants Total number of study participants will be 75-90, consisting of overweight men&#xD;
      and women, 18-45 years of age.&#xD;
&#xD;
      Treatment Dietary supplement consisting of probiotic capsules called LB001. It contains&#xD;
      strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of&#xD;
      Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other&#xD;
      ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts&#xD;
      from vegetable fatty acids. The capsule shell is made of vegetable&#xD;
      HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram. The placebo is&#xD;
      made of rice flour.&#xD;
&#xD;
      Since one of the inclusion criteria is &quot;willingness to lose weight&quot;, all study participants,&#xD;
      regardless of randomized treatment, will receive general advice regarding healthy lifestyle&#xD;
      habits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight change</measure>
    <time_frame>Baseline, 3-month follow-up</time_frame>
    <description>Weight will be measured in kilograms using a scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Baseline, 3-month follow-up</time_frame>
    <description>Participants waist circumference will be measured using a standard tape measure (in cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline, 3-month follow-up</time_frame>
    <description>Glycated hemoglobin A1c will be measured in blood (mmol/mol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>Baseline, 3-month follow-up</time_frame>
    <description>High-density lipoproteins will be measured in plasma (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Baseline, 3-month follow-up</time_frame>
    <description>Triglycerides will be measured in plasma (mmol/L)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four capsules containing rice flour will be given to the placebo group daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two capsules of probiotics and two capsules of placebo daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.&#xD;
The placebo is made of rice flour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LB001</intervention_name>
    <description>Probiotics</description>
    <arm_group_label>Double dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 26.0 - 29,99 kg/m2&#xD;
&#xD;
          -  18-45 years old&#xD;
&#xD;
          -  Willingness to lose weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active weight loss in the last three months&#xD;
&#xD;
          -  The desire for or planned pregnancy upcoming months&#xD;
&#xD;
          -  Chronic somatic diseases that may affect metabolic and/or intestinal function (e.g.&#xD;
             diabetes, hypertension, dyslipidemia, Irritable Bowel Disorder (IBD), gluten&#xD;
             intolerance, pancreatic dysfunction, other causes of malabsorption, neoplastic&#xD;
             disease)&#xD;
&#xD;
          -  Allergies with previous anaphylactic reactions&#xD;
&#xD;
          -  Abdominal surgery six months prior to inclusion&#xD;
&#xD;
          -  Current or history of eating disorders&#xD;
&#xD;
          -  Extreme or unusual diets for the last three months, which the investigator considers&#xD;
             could negatively affect the outcome of the study&#xD;
&#xD;
          -  Psychiatric disorders (e.g., schizophrenia, and other diagnoses that may influence&#xD;
             compliance)&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Continuous oral pharmacological treatment and other types of pharmacological treatment&#xD;
             that may influence the study&#xD;
&#xD;
          -  Present or recent usage of other probiotic agents&#xD;
&#xD;
          -  Other conditions which the investigator considers could negatively affect the outcome&#xD;
             of the study or study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilia Hagman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilia Hagman, PhD</last_name>
    <phone>0046 8 585 874 23</phone>
    <email>emilia.hagman@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pernilla Danielsson, PhD</last_name>
    <phone>0046 8 585 874 23</phone>
    <email>pernilla.danielsson.liljeqvist@ki.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska Institutet, Department of Clinical Science, Intervention and Technology</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>141 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Hagman, PhD</last_name>
      <phone>+46 707157298</phone>
      <email>emilia.hagman@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Emilia Hagman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

